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Abstract
Background: Production of high levels of IL-6 is often correlated with resistance to cytotoxics or ionizing radiations, in
cancer cell lines as in various cancer patients. We investigated whether monoclonal antibodies directed against IL-6 may
enable to reverse resistance of cancer cell lines.
Methodology/Principal Findings: We exposed ten haematological cancer cells from lymphoma, myeloma, or leukemia
origins to cytotoxics or ionizing radiations and assessed the effects of anti–IL-6 antibody addition on cell proliferation,
apoptosis, or IL-6 signaling. A strong correlation between IL-6 secretion, measured by ELISA, and resistance to doxorubicin
as ionizing radiations was observed in the multiple myeloma U266 and the Burkitt’s lymphoma Daudi and Namalwa cells.
Although an anti–IL-6 antibody combined to both treatments efficiently blocked IL-6 signaling in U266 cells, expressing the
IL-6 receptor gp80, it did not increase treatment-induced anti-proliferative and pro-apoptotic effects on these cells, as well
as on Daudi and Namalwa cells. This lack of effect could be related to diverse factors: 1) a higher release of the soluble form
of IL-6 receptor gp80 in response to doxorubicin and irradiation from all cell lines, 2) an impaired level of the IL-6 pathway
inhibitor SOCS3 in Daudi cells, and 3) an increased release of IL-10 and TNFa, two cytokines involved in cell radio- and
chemoresistance.
Conclusions/Significance: These data support the fact that IL-6 is not the preponderant actor of cell resistance to cytotoxics
and ionizing radiations, which seems to be regulated by a complex network of proteins.
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Introduction
Interleukin-6 (IL-6) is a key cytokine mainly produced by a
broad variety of cell types including monocytes, fibroblasts,
endothelial cells, and epithelial as haematological tumour cell
lines [1]. IL-6 is particularly involved in immune response,
inflammation and in haematopoiesis by controlling proliferation
and maturation of B and T cells and differentiation of cytotoxic T
cells, macrophages and megakaryocytes. Besides, IL-6 promotes
the proliferation of haematological malignancies (leukemia,
lymphoma and myeloma), and solid tumours (breast and renal
adenocarcinoma or Kaposi sarcoma) [1,2], through an intracrine,
autocrine and paracrine mode of action [3,4]. Finally, a high IL-6
serum level is often associated to worse progression-free survival
and overall survival in Non Hodgkin Lymphoma [5], myeloma
[6], renal carcinoma and breast adenocarcinoma [7,8].
IL-6 exerts its biological effects through binding to its ligand-
binding receptor gp80 and thereupon to two signal transducing
receptor subunits gp130 [9]. IL-6 binding results in gp130
dimerization and in the subsequent activation of Janus kinases,
which activate in turn gp130 through phosphorylation of its
intracellular domain. Phosphorylated tyrosines in gp130 form
docking sites for SH2 domain containing proteins like activators of
transcription STAT1 and STAT3 [10]. Optimal activation of
STAT3 requires phosphorylation of its tyrosine 705 along with
phosphorylation of the serine 727 residue. In parallel, gp130
activation results in the activation of Raf/Ras/MEK cascade, and
finally in phosphorylation and subsequent activation of p42 and
p44 [11]. Finally, tyrosine motifs in gp130 are also crucial for
recruitment of the feedback inhibitor SOCS3 (suppressor of
cytokine signaling 3), which modulate IL-6 signaling via Jak
inactivation and inhibition of STAT3/gp130 contact [12].
Despite the improvement of current therapies, most cancers in
advanced phase develop intrinsic or acquired resistance [13].
In vivo in man, resistance to cytotoxics is associated with the
overproduction of several cytokines, in particular IL-6, IL-10,
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(Tumour Necrosis Factor) [7,14–17]. In vitro, IL-6 protects M1
myeloid leukemia cells against apoptosis induced by cytotoxic
drugs [18], but also renal carcinoma cells (RCC), erythro-leukemic
cells and myeloid leukemia cells against the effects of cisplatin
[16,19,20]. IL-6 may also be responsible for tumour cell resistance
to ionizing radiations in B cells or oral cancer cells [21,22],
through a STAT3-dependent pathway [21]. Interestingly, in
addition to the presence of baseline levels of IL-6, an overpro-
duction of this cytokine in serum often occurred following
irradiation of patients with breast, sarcoma, liver or head and
neck cancers [23,24]. Monoclonal antibodies blocking molecules
which protect cells against cytotoxic agents, may enable reverting
resistance [25]. Anti-IL-6 antibodies emerge as a new therapeutic
adjuvant option for patients attained of haematological cancers, as
strengthened by preclinical works using anti-IL-6 antibodies with
cis-diamminedichloroplatinium (CDDP) in RCC [16] or melpha-
lan in advanced multiple myeloma [26].
In the present work, we investigated the capacity of a targeted
therapy directed against IL-6 to modulate cellular resistance to
radiotherapy and chemotherapy. Following the precise identifica-
tion of tumour cell dependence for IL-6 (expression of IL-6 and its
receptor IL-6R) in a panel of ten cell lines (of myeloma, leukemia
or lymphoma origins), we determined their individual response to
different doses of radiations and chemotherapeutic drugs. Thus,
we selected a panel of four cells with differential chemo- and
radiosensitivity and various expression levels of IL-6 as IL-6R, and
tested the effect of anti-IL-6 antibodies on cell proliferation,
apoptosis and IL-6-dependent cell signaling in combination with
cytotoxics.
Results
Interleukin-6, IL-6 receptor expression, and resistance to
cytotoxics
The mRNA and protein expression of IL-6 and its two receptor
subunits gp130 and gp80 was assessed in a panel of nine
haematologic tumour cell lines, using flow cytometry, ELISA
and RT-PCR, comparing with the triple positive control U266
cells. All cell lines expressed both soluble and membrane forms of
gp130, except U937 and BJAB cells which expressed membrane
gp130 only (Table 1). U937, BJAB and RPMI8226 cells expressed
both soluble and membrane bound gp80 forms. Daudi and BL-36
cells also expressed the soluble form of gp80, while Raji and
Namalwa were negative for both gp80 forms. Only the four
Burkitt’s lymphoma Raji, Daudi, BL-36 and Namalwa cells
expressed IL-6; this latter expressed very low level IL-6, weakly
detectable by PCR (Figure S1).
Cell proliferation was measured 24, 48 or 72 h following
exposure to ionizing radiations (7, 15 and 30Gy, as previously
reported [27,28]), using an ATP-based proliferation assay and a
thymidine incorporation assay. Results with both tests were
consistent as shown in Figure S2 for Daudi cells. For convenience,
we used ATP based assay in the following experiments. Raji,
Ramos, U937 and Rs4; 11 cells were classified as sensitive to
radiation exposure since proliferation was reduced by 50% at least
48 h following an exposure to 30Gy (Figure 1A). BJAB,
RPMI8226, U266, BL-36, Namalwa and Daudi cells were
resistant to any dose of radiations since more than 50% of cells
continue to proliferate 48 h after irradiation. Cells were also
exposed to doxorubicin, vinblastine and taxol at 0.01, 0.1 and
1 mg/mL or to vincristine and cisplatin at 0.1, 1 and 10 mg/mL for
24, 48 or 72 h, as previously described [17,29,30]. All cell lines
were resistant to a 48 h exposure to cisplatin at 1 mg/mL, except
Namalwa cells (Figure 1B). Most of cell lines were highly sensitive
to vinblastine, vincristine and taxol, when U266, Ramos and BJAB
cells were more resistant to these drugs (40–50% proliferation after
48 h exposure). U937, Rs4; 11, BJAB and RPMI8226 cells were
highly sensitive to doxorubicin (Figure 1C and Table 2),
comparing with Raji, Ramos, Namalwa and Daudi cells which
displayed a partially resistant pattern. U266 and BL-36 cells were
strongly refractory to this drug (Figure 1B).
Thus, cells producing IL-6, e.g. U266, BL-36, Namalwa and
Daudi cells,weresignificantly more resistantto theanti-proliferative
effect of cytotoxics, as shown in Figure 1D (p%0.05). To further
investigate this question, four cell lines were selected for subsequent
experiments: 1) the multiple myeloma U266 cells as a reference,
expressing IL-6 and both IL-6R chains, and moderately affected by
ionizing radiationsas chemotherapy,2) Daudi,a cell line resistantto
radiotherapy, poorly affected by doxorubicin and cisplatin,
Table 1. Detection of membranous and soluble forms of gp130 and gp80 and detection of IL-6 in tumour cell lines.
Membranous form (% positive cells) Soluble form (pg/mL)
gp130 gp80 IL-6 gp130 gp80 IL-6
U266 71 91 64 3226101 673962372 34623
RPMI8226 26 24 0 10056475 470661410 0
U937 75 80 0 0 18786567 0
Rs4; 11 72 1 0 62678 0 0
Raji 82 66 57 94655 0 13612
BL-36 87 1 51 4226288 3586148 867
Daudi 74 3 68 66697 1696154 1367
Ramos 89 3 0 3716200 0 0
BJAB 70 92 0 0 6656258 0
Namalwa 78 3 59 66692 0 865
Membrane staining of gp130 and gp80 and intracellular staining of IL-6 were performed on 2610
5 cells as described in materials and methods with 1 mg/mL primary
antibody. Results were expressed as the mean % of positive cells of two independent experiments realized in duplicate. IL-6, soluble gp130 (sgp130) and sgp80 were
measured by ELISA on 100 mL supernatants as described in materials and methods. Results were expressed as the mean6SD of three independent experiments realized
in duplicate (pg/mL).
doi:10.1371/journal.pone.0008026.t001
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similar to Daudi cells, exceptforits highersensitivity to cisplatinand
its lack of gp80, and finally 4) U937 cells, sensitive to cytotoxics and
radiotherapy, which did not secrete IL-6 but expressed both
membrane IL-6 receptor chains (Figure S1).
IL-6 signaling inhibition by anti–IL-6 antibody in U266 cells
Following these observations, we assessed the effect of a brief
exposure of U266 cells (5, 15, 30 or 60 min) to an antibody raised
againstIL-6, in the presence of exogenous IL-6, on the main actors of
IL-6 pathways, STAT and p42/p44. As shown in Figure 2A,
Figure 1. Cell response to anticancer treaments. (A) Response to radiation exposure. Following an irradiation at 30Gy, cells were plated in 96
well plates at 5,000 cells/well. An ATP-based proliferation assay was conducted 48 h after, as described in materials and methods. Results were
expressed as the percentage of proliferation=number of irradiated cells at 48 h/number of cells at t0 in control conditions 61006S.D, and
represented the mean of three experiments realized in duplicate. The p value was determined according to a paired T-test * p,0.05. (B,C) Response
to cytotoxics. Cells were exposed to doxorubicin, vinblastine and taxol at 0.1 mg/mL, to vincristine and cisplatin at 1 mg/mL in a 96 well plate at
5,000 cells/well for 48 h. An ATP-based proliferation assay was conducted as described in materials and methods. Results were expressed as the % of
proliferation=number of treated cells at 48 h/number of cells at t0 in control conditions61006S.D and represented the mean of two independent
experiments realized in duplicate. (D) Correlation between IL-6 secretion and radioresistance. This box-plot compiled data from ELISA assay described
in Table 1 and % proliferation of cells 24 h after an irradiation at 30Gy. We divided cells into two groups, cells which did not secrete IL-6 (IL-6=0) and
cells producing IL-6 (IL-6.8, minimal value obtained for BL-36 and Namalwa cells). The p value was calculated according a Wilcoxon statistical test.
doi:10.1371/journal.pone.0008026.g001
Table 2. Synthesis of cell sensitivity to cytotoxics.
U266 Namalwa Daudi BL-36 Raji RPMI 8226 BJAB U937 Ramos Rs4; 11
Dox 2 ++ /22 +/2 ++ + + /22
CDDP 2 + 222 2 2 22 2
VBL/Tax/VCR +/2 + +++ + + /2 ++ /2 +
Cells were exposed to doxorubicin, vinblastine and taxol at 0.1 mg/mL, to vincristine and cisplatin at 1 mg/mL in a 96 well plate at 5,000 cells/well for 48 h. An ATP-based
proliferation assay was conducted as described in materials and methods. (2): resistance=proliferation .50%, (+/2) intermediate sensitivity=30%, proliferation
,50%, (2) sensitivity=proliferation ,30%.
doi:10.1371/journal.pone.0008026.t002
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maximal STAT3 phosphorylation was observed on Tyr705 (p-
STAT3-Tyr705) at 15 min, while Ser727 phosphorylation peaked at
30 min. The level of p42/p44 and STAT3 was marginally affected
by IL-6. The addition of anti-IL-6 antibodies successfully blocked
STAT3 and p42/p44 phosphorylation, particularly after 30 and
60 min exposure. The isotype-matched control antibody had no
impact on the phosphorylated form of p42/p44 and STAT
(Figure 2B).
In contrast, the same experiments conducted on Namalwa as
well as Daudi cells showed no effect of this antibody on IL-6
signaling in these cells (Figure 2C). In particular, p-STAT3-Tyr
705 was undetectable in Daudi and Namalwa cells. Thus, we
hypothesized that Daudi cells were poorly responsive to IL-6
inhibition in absence of exogenous IL-6 plus gp80. We tested the
concomitant exposure of Daudi cells to gp80 and IL-6 for
60 min, which was the best time observed for antibody-induced
inhibition in U266 cells in Figure 2A. This revealed a weak
inhibitory effect of anti-IL-6 antibody on the level of p42/p44
phosphorylated form (Figure 3). As a control, we similarly
exposed Daudi cells to the same quantity of soluble form of IL-2
receptor. This induced a decrease in the phosphorylated form of
p42/p44 and p-STAT3 on Ser727. As previously shown by
others, IL-2 activatesthe MAP kinase pathway [31], aswell as the
phosphorylation of STAT3 [32]. By trapping IL-2, it is therefore
consistent that the soluble form of IL-2R decreases IL-2R
activation and downstream phosphorylation of its two STAT and
p42/p44 target proteins.
p-STAT3-Tyr705 impairment in U266 and U937 cells
exposed to anti–IL-6/chemotherapy or
anti–IL-6/radiotherapy combinations
We then studied the influence of chemotherapy and radiother-
apy in combination with an anti-IL-6 antibody on the phosphor-
ylated form of STAT3 on Tyr705 in U266 and U937 cells. No
phosphorylation of STAT3 in control conditions and after 7Gy
radiations was observed for U937 (Figure 4A) nor for U266 cells
(Figure 4B). In the presence of exogenous IL-6, the anti-IL-6
Figure 2. IL-6–induced phosphorylation of STAT3 and p42/p44 was efficiently reduced by an anti–IL-6 in U266 but not in Daudi
cells. (A,B) U266 cells were exposed to 10 ng/mL IL-6 or not (NT) with or without 10 mg/mL anti-IL-6 (A) or IgG1 control (B) for 5, 15, 30, or 60 min.
30 mg of total proteins were analyzed with anti-phospho-STAT3 (Ser727 or Tyr705), phospho-p42/p44, STAT3 or p42/p44 at a dilution 1/1,000 and
revealed with anti-rabbit-HRP 1/100,000, as described in materials and methods. (B) Daudi cells were exposed to 10 ng/mL IL-6 or not (NT) with or
without 10 mg/mL anti-IL-6 for 5, 15, 30, or 60 min. 50 mg of total proteins were analyzed with phospho-p42/p44, STAT3, or p42/p44 at a dilution
1/200 and revealed with anti-rabbit-HRP 1/50,000, as described in Materials and Methods.
doi:10.1371/journal.pone.0008026.g002
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blocked STAT3 phosphorylation on Tyr705 in both U937 and
U266 cells. The phosphorylated form of STAT3 on Ser727 was
weakly increased by radiations. Similarly, no phosphorylation of
STAT3 on Tyr705 was observed after an exposure of U937 and
U266 cells to 1 mg/mL cisplatin and 0.1 mg/mL doxorubicin
(Figure 4B and 4D, respectively). However, STAT3 phosphory-
lation on Tyr705 was successfully impaired in these cells by the
anti-IL-6 antibody, alone or in association with chemotherapeutic
drugs, in the presence of exogenous IL-6.
IL-6 and SOCS3 transcription in Daudi and U266 cells
exposed to exogenous IL-6
Since Daudi response to IL-6 and to anti-IL-6 antibody differed
from U266 cells, we could hypothesize that IL-6 pathway is not
similarly regulated in these two cell lines. It was previously shown
that SOCS expression and particularly SOCS3 was regulated by a
number of cytokines including IL-6 [33], and that SOCS3
modulated STAT activity [12]. After 1 h, IL-6 and SOCS3
mRNA level was similar in U266 (data not shown) and in Daudi
cells (Figure 5A), in the presence of exogenous IL-6 or not, ruling
out SOCS3 as responsible for the different IL-6 response in U266
and Daudi cells in these conditions.
IL-6 inhibition has a minor effect on cell proliferation and
apoptosis
The four cell lines were exposed to 1 mg/mL cisplatin or
0.1 mg/mL doxorubicin in combination with anti-IL-6 antibod-
ies for 48 h. In parallel, U266 and U937 cell proliferation was
determined 48 h after exposure to a 7Gy dose of radiotherapy
instead of 72 h for the more radio-resistant Daudi and Namalwa
cells. In these tests, 10, 1 or 0.1 mg/mL antibodies were used
with different modalities: 72 h pre-incubation, a concomitant
Figure 3. IL-6 induced p42/p44 phosphorylation was efficiently
reduced by an anti–IL-6 antibody in the presence of exogenous
gp80 in Daudi cells. Daudi cells were exposed to 10 ng/mL IL-6 +/2
50 ng/mL soluble gp80 or IL-2R with or without 10 mg/mL anti–IL-6 for
60 min. 50 mg proteins were analyzed with anti-phospho-STAT3 (Ser727
or Tyr705), phospho-p42/p44, STAT3, or p42/p44 at a dilution 1/200 and
revealed with anti-rabbit-HRP 1/50,000, as described in Materials and
Methods.
doi:10.1371/journal.pone.0008026.g003
Figure 4. Anti–IL-6 antibody efficiently blocked IL-6 signaling in association with radiotherapy and chemotherapy on U937 and
U266 cells. Following an irradiation at 7Gy, U937 (A) and U266 (B) cells were exposed to 10 ng/mL IL-6 with or without 10 mg/mL anti–IL-6 antibody
for 1 h. 50 mg of total proteins were analyzed with anti-phospho-STAT3 (Ser727 or Tyr 705) or anti-STAT3 at a dilution 1/1,000 and revealed with anti-
rabbit-HRP 1/50,000 as described in materials and methods. U937 (C) and U266 (D) cells were exposed to 10 ng/mL IL-6 with or without 10 mg/mL
anti-IL-6 antibody in the presence of 1 mg/mL cisplatin or 0.1 mg/mL doxorubicin. 50 mg of total proteins were analyzed as previously.
doi:10.1371/journal.pone.0008026.g004
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IL-6 (see Table 1 and Figure S1), 10 ng/mL IL-6 was added in
U937 cell culture medium. The addition of anti-IL-6 antibody
did not affect the proliferation of cell lines exposed to radiation
therapy or chemotherapy, in any of the four cell lines, regardless
of the dose and the sequence of administration. As shown in
Figure 6A, an anti-IL-6 antibody exerted a minor effect on
Daudi, U937 and Namalwa cell growth in association with 7Gy
radiations (220% non significant, paired T-test). Similar results
were obtained for cisplatin and doxorubicin (data not shown). A
lack of effect of IL-6 inhibition was also observed for BL-36 and
Raji cells, the two other cell lines secreting IL-6 and resistant to
radiations. A tritiated thymidine assay conducted on Daudi cells
showed that an anti-IL-6 treatment significantly, although
weakly, improve the cytostatic effects induced by radiations
(Figure S3A) but not those induced by doxorubicin (Figure S3B).
The length of treatment was not the limiting factor since an
exposure of Daudi cells to anti-IL-6 for 7 days was also
inefficient (Figure S3C). As a control, IL-6 involvement in cell
resistance was only observed in two cases in our study: 1) IL-6
protected U937 cells from radiations; this protection was non-
significantly decreased by an anti-IL-6 (Figure S4A); 2) anti-IL-6
antibody was able to increase dexamethasone-induced cytotoxic
effects on Daudi cells, alone or in association with doxorubicin
(Figure S4B). Finally, anti-IL-6 antibodies marginally increased
the percentage of (Annexin V+)a n d( A n n e x i nV / P I +)D a u d i
cells (Figure 6B). Similar results were obtained for chemother-
apy. This was confirmed by the lack of modification of caspase
activity (Figure S5). Altogether, these data suggest that IL-6
blocking in association with doxorubicin and radiations did not
affect significantly the cytotoxic effects of these treatments on the
cells we studied.
SOCS3 transcriptional repression in Daudi cells following
long-term exposure to radiations, doxorubicin, and
anti–IL-6 antibody
We determined the level of IL-6 and SOCS3 mRNA in U266
and Daudi cells after long-term anticancer treatments by RT-
qPCR. IL-6 mRNA level was stable in U266 as well as in Daudi
cells after 48 h regardless of the treatment (Figure 5B). SOCS3 was
Figure 5. SOCS3 mRNA level is decreased in Daudi cells after 48 h exposure to doxorubicin, IL-6 antibody, and ionizing radiations.
(A) Daudi cells were exposed or not to 10 ng/mL IL-6 with or without 10 mg/mL IgG1 or anti–IL-6 for 1 h. 1 mg RNA extracted from 2610
6 cells were
subjected to RT–qPCR to measure IL-6 (X) and SOCS3 (&) mRNA level as described in materials and methods. Results were presented as relative
expression of gene of interest related to tubulinA expression and normalized to untreated cells at t time. (B) 1 mg RNA was subjected to RT–qPCR for
IL-6 mRNA measurement following U266 (%) or Daudi cell (&) exposure to 0.1 mg/mL doxorubicin, 1 mg/mL cisplatin, 10 mg/mL IgG1, or anti–IL-6
and 7Gy ionizing radiations for 48 h, as described in Materials and Methods. Results were expressed as IL-6 mRNA level related to tubulinA mRNA as
compared to untreated cells and represented the mean of two independent experiments. The p value was determined according to a paired T-test.
(C,D) 2610
6 Daudi cells were exposed to 0.1 mg/mL doxorubicin, 1 mg/mL cisplatin, 10 mg/mL IgG1, or anti–IL-6 and 7Gy ionizing radiations for 48 h.
1 mg RNA extracted from these cells was submitted to RT–qPCR to measure SOCS3 mRNA level. (C) raw data plot, (D) relative mRNA level. Results
were presented as relative expression of SOCS3 related to tubulin A and to non-treated cells at t time and represented the mean6S.D of four
independent experiments. The p value was determined according to a paired T-test * p,0.05, **,0.01, ***,0.001.
doi:10.1371/journal.pone.0008026.g005
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exposure of Daudi cells to doxorubicin, radiations or anti-IL-6
antibodies significantly decreased SOCS3 mRNA level; this was
not observed with cisplatin (Figure 5C and 5D). The addition of
anti-IL-6 to doxorubicin or to radiations did not further decrease
SOCS3 mRNA level as compared to anticancer treatments alone
(data not shown).
IL-6 secretion in response to doxorubicin and ionizing
radiations
An overproduction of IL-6 following irradiation of patients
attained of various cancers had been previously suggested [23,24].
In the same way, cisplatin increased IL-6 production in erythro-
leukemic [19] or oral cancer cells [22]. We therefore investigated
IL-6 secretion by the four selected cell lines following exposure to
cytotoxics and radiotherapy. Exposure to ionizing radiations
induced IL-6 release from Daudi and U266 cells: a 3-fold
increase was observed for U266 and Namalwa cells and a 4-fold
increase for Daudi cells (Figure 7A). Doxorubicin at 0.1 mg/mL
increased by 4-fold IL-6 release from Daudi and U266 cells
(instead of 1.5-fold for Namalwa cells). IL-6 measurements
following kinetic experiments revealed that the induction of IL-6
secretion by doxorubicin occurred from 32 h for U266 and 24 h
for Daudi cells (Figure 7B). In contrast, cisplatin had little effect on
IL-6 release in all cell lines (data not shown). As previously shown
in Figure 5A and 5B, kinetic experiments performed by RT-qPCR
revealed no change of IL-6 mRNA level in Daudi and U266 cells
during cell exposure to doxorubicin, as well as irradiation, still
48 h. Thus, doxorubicin and radiation-based treatments main-
tained IL-6 mRNA level through 1) a balance between mRNA
synthesis and a lack of protein degradation, or 2) through mRNA
stabilization before its secretion.
Figure 6. IL-6 inhibition in combination with 7Gy radiations did not inhibit U266, U937, Daudi, and Namalwa cell proliferation. (A)
Cells were irradiated at 7Gy (&) or not (%). After irradiation, cells were resuspended into fresh medium, plated in 96 well plates at 5000 cells/well and
exposed to 10 mg/mL IgG1 or anti–IL-6. U937 cells were also exposed to 10 ng/mL IL-6. Cell growth was measured 48 h later for U266 and U937 cells
and 72 h later for Namalwa and Daudi cells with 20 mL reagent for 10 min. Results were expressed as relative proliferation=number of irradiated cells
at t time/number of cells at t0 in control conditions6S.D and represented a significant experiment among two realized in duplicate. The p value was
determined according to a paired T-test. (B) Daudi radio-induced apoptosis was not improved through IL-6 inhibition. Cells were irradiated at 7Gy
(lower panel) or not (NI, upper panel). After irradiation, cells were resuspended into fresh medium, plated in 6 well plates at 200,000 cells/well and
exposed to 10 mg/mL IgG1 or anti–IL-6 antibody. Annexin V/PI labeling was realized on 2610
5 cells as described in Materials and Methods. Numbers
indicated the % of cells present in each quadrant.
doi:10.1371/journal.pone.0008026.g006
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and radiotherapy
In parallel to IL-6 measurements, we assessed the level of the
soluble and agonist form of gp80 by ELISA in the same conditions.
As for IL-6, gp80 release was found to increase in response to
doxorubicin as well as ionizing radiations in U266 and Daudi cells
(3-fold for doxorubicin and 2-fold for 7Gy, Figure 7C). To
investigate whether the concomitant release of sgp80 could
counteract the inhibitory effect of the anti-IL-6 antibody, we
tested the addition of an anti-gp80 antibody to irradiated Daudi
cells: this was found to weakly increase the anti-proliferative effects
of radiations associated to anti-IL-6 antibodies (Figure 7D). Similar
results were obtained with cisplatin, although this drug did not
induce IL-6 and gp80 release from Daudi cells.
IL-10 as TNFa secretion by U266 and Daudi cells in
response to doxorubicin and ionizing radiations
Thus we measured the level of other cytokines potentially
involved in treatment resistance like IL-10 and TNFa [34,35]. IL-
10 and TNFa are well-known growth factors for lymphoma and
myeloma cell lines [36,37]. First, we could notice that cells
resistant to treatments (U266, Daudi and Namalwa cells) secreted
a high level of these cytokines, particularly TNFa for U266 and
Daudi cells and IL-10 for Namalwa cells, in marked contrast with
the sensitive U937 cell line, whose production was limited
(Figure 8A and 8B). Cytokine secretion strongly correlated with
cell resistance to treatments, as revealed by the box-plots in
Figure 8C and 8D (p,0.05). Interestingly, doxorubicin enhanced
TNFa secretion by Daudi cells, contrary to radiations which
increased IL-10 release by these cells. Similar results were
obtained for Namalwa cells, but in a non significant manner.
The observation of a correlation between baseline and anticancer
treatment-induced production of TNFa and IL-10 with resistance
suggests that multiple cytokines contribute to resistance in these
cell lines, as described previously in our lab [17].
Discussion
This study revealed that a potent correlation exists between IL-6
expression by oncohaematologic cells and their resistance to
conventional treatments: U266, BL-36, Daudi and Namalwa cells
expressing IL-6 constitute the most resistant cells to radiations and
doxorubicin (Table 1 and Figure S1, S2). IL-6 inhibition
Figure 7. Anticancer treatments induced IL-6 secretion without affecting its mRNA level. (A) IL-6 level in cell medium was determined in
100 mL supernatants of U266 (%), Daudi (&), or Namalwa (&) cells, collected 72 h following an irradiation at 7Gy or not (NI) or after 48 h exposure to
0.1 mg/mL doxorubicin or not (NT), as described in materials and methods. Results were presented as (IL-6) in pg/mL secreted by 10
8 cells at day of
the assay per 24 h. (B) IL-6 secretion following exposure of U266 (X) or Daudi cells (&) to 0.1 mg/mL doxorubicin for 8, 24, 32, and 48 h. Results were
presented as (IL-6) in pg/mL secreted by 10
8 cells at day of the assay per 24 h and represented the most significant experiment. The p value was
determined according to a paired T-test * p,0.05, **,0.01. (C) 7Gy radiations and doxorubicin induced soluble gp80 release. Cell supernatants were
collected 48 h after exposure to 0.1 mg/mL doxorubicin or not (NT) and 72 h after a 7Gy irradiation or not (NI). Sgp80 was measured by ELISA on
100 mL supernatants. Results were expressed as the concentration of gp80 in pg/mL for 10
8 cells at day of the assay per 24 h and represented the
mean of two experiments performed in duplicate. The p value was determined according to a paired T-test * p,0.05, **,0.01. (D) Daudi cells were
irradiated at 7Gy. After irradiation, cells were re-suspended into fresh medium, plated in 96 well plates at 5,000 cells/well and exposed to 10 mg/mL
anti-IL6 or IgG1 in the presence of 10 mg/mL anti-gp80 B-R6 or not (NT). Cell growth was measured 72 h later with 20 mL reagent for 10 min. Results
were expressed as relative proliferation=number of irradiated cells at t time/number of cells at t0 in control conditions6S.D and represented a
significant experiment among two realized in duplicate. The p value was determined according to a paired T-test * p,0.05, **,0.01.
doi:10.1371/journal.pone.0008026.g007
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U266 and U937 cells, and particularly reduced STAT3 phos-
phorylation on Tyr705, on its own and in the presence of
doxorubicin as cisplatin, or following irradiation at 7Gy (Figure 2
and Figure 4). In contrast, IL-6 inhibition marginally affected the
level of p-STAT3 on Ser727. The function of this phosphorylated
residue is always nowadays much debated: some labs suggested
that this phosphorylation was required for STAT homo-dimer-
ization and DNA binding [38], contrary to others supporting its
role for the transcriptional activation of its targets through its
association with Pin1 and p300 [39,40]. Chung et. al showed that
the phosphorylation of STAT3 on Ser727 is due to p42/p44 and
that an inverse correlation between Ser727 phosphorylation and
that on Tyr 705 exists [41]. Although p-p42/p44 level was
impaired through IL-6 inhibition in U266 and Daudi cells
(Figure 2A and Figure 3, respectively), the level of p-STAT3-
Ser727 was increased in U266 cells after 30 and 60 min exposure
to IL-6, but was also elevated in U266 and U937 cells following
radiation or chemotherapy treatments (Figure 4). This suggests
that 1) other kinases than p42/p44 regulate STAT3 phosphory-
lation on Ser727 in our models, and that 2) this hyperpho-
sphorylated form of STAT3 could be more active for the
transcription of its targets.
Daudi and Namalwa cells were unresponsive to endogenous as
exogenous IL-6 signal, as revealed by western-blot analysis
through p-STAT3 measurement (Figure 2C and data not shown).
Nevertheless, a reduced level of phospho-p42/p44 was observed in
Daudi cells after a brief exposure to IL-6 associated to anti-IL-6
signals if exogenous gp80 was concomitantly added (Figure 3). A
similar observation has been recently made for U266 cells exposed
to the proteasome inhibitor bortezomibH combined to the NFkB
inhibitor 6-amino-4-quinazoline [42]. These two agents only
efficiently interfered with IL-6 induced phosphorylation of STAT3
and p42/p44 if soluble gp80 was added.
Although resistant cells responded to radiations as well as
cytotoxics by an IL-6 release (Figure 7), an anti-IL-6 antibody was
poorly efficient to counteract cell resistance, as revealed by the
measurement of cell growth and apoptosis (Figure 6, Figure S3,
and Figure S5). Altogether, it seems that IL-6 inhibition combined
to anticancer treatments efficiently negates IL-6 signaling for short
time but looses its potency on general physiological processes after
a longer. This could be linked to a counterbalanced mechanism
Figure 8. 7Gy radiations and doxorubicin induced IL-10 and TNFa release from Daudi and Namalwa cells. Cell supernatants were
collected 48 h after exposure to 0.1 mg/mL doxorubicin (&) and after a 7Gy irradiation (&) or not (NT,%). IL-10 and TNFa levels were measured by
ELISA on 100 mL supernatants as described in materials and methods. Results were expressed in pg/mL for 10
8 cells at day of the assay per 24 h as the
concentration in experiments performed in duplicate. The p value was determined according to a paired T-test. (C,D) Correlation between IL-10 and
TNFa secretion and resistance to treatment. These box-plots compiled data from ELISA assays described in (A,B) and cell response to treatment
showed in Figure 1. We divided cells into two groups, cells which were resistant to radiations (&) as well as doxorubicin (Daudi, U266, and Namalwa
cells whose proliferation .50% after 48 h treatment) and U937 sensitive cells whose proliferation ,50% after 48 h treatment (%). The p value was
calculated according a Wilcoxon statistical test.
doi:10.1371/journal.pone.0008026.g008
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expression and secretion of the agonist receptor gp80 (Figure 7C).
Thus, a potent therapeutic alternative could be the association of
an anti-IL-6 with an anti-IL-6R like tocilizumab, as suggested by
the improved inhibitory effect of anti-IL-6 associated to anti-gp80
on Daudi cell growth (Figure 7D). A work of Mizutani et al.
strengthened this idea, since an anti-IL-6R sensitized RCC to
cisplatin [16].
We could not rule out that IL-6 acts as an intracrine growth
factor in the cells we selected, since an old study showed that an
anti-IL-6 antibody did not inhibit U266 and RPMI8226 cell
growth [43]. Although anti-IL-6 combined to exogenous IL-6
could abrogate IL-6 signaling pathways in U266 and Daudi cells
(Figure 2 and Figure 3), silencing IL-6 through the use of RNA
technology could confirm this hypothesis. Such an intracrine loop
has been previously identified in our lab for RCC, through the use
of antisense oligonucleotide [3], and corroborated by the anti-IL-6
antibody inefficiency on radioresistant RCC. A previous study by
Mizutani and coworkers on RCC cells similarly showed that anti-
IL-6 as anti-IL-6R antibodies were only efficient on freshly patient
derived RCC in association with cisplatin [16], through the down-
regulation of Glutathione S Transferase-p (GST) mRNA. In our
case, GST is not necessarily implicated in cell resistance to
doxorubicin or radiations. Finally, we could not ignore the
essential impact of tumour environment on cell survival and
growth and could imagine that IL-6 inhibition through the use of
anti-IL-6 antibodies could block cytokine pools secreted by the
neighboring cells and thus could reveal a potent benefit in vivo.
Despite IL-6 involvement in cancer cell resistance was well
established for various types of cancers [19,21], this cytokine did
not set itself up as the main actor of radio-and chemoresistance of
Daudi and Namalwa cells, since they were weakly sensitive to anti-
IL-6 antibodies. Two previous studies examined the effect of an
anti-IL-6 in association with cisplatin on cancer cells. Dedoussis et
al. showed that an anti-IL-6 combined to cisplatin exerts a
synergistic cytotoxic effect (only around 20%) on K562 erythro-
leukemic cells [19]. Borsellino et al. revealed that an anti-IL-6
antibody efficiently promotes a cytostatic effect on prostate cancer
cells exposed to cisplatin in a sequential dependent manner
(around 40% cytotoxicity) [44]. Thus, IL-6 seems to be partially
involved in chemoresistance and only for a panel of agents, as
suggested by the difference of cell behaviour in response to
cisplatin and doxorubicin in our work: no release of IL-6 in
response to cisplatin contrary to doxorubicin (Figure 7).
However, a lack of efficiency for antibody based treatment plus
cisplatin had been previously observed for Rituximab on Daudi
cells [14]. This study revealed that the anti-CD20 antibody has no
effect on Daudi and Ramos cells but acts synergistically with
cisplatin on the two non-Hodgkin’s lymphoma 2F7 and 10C9
cells, resulting in the down-regulation of IL-10, another cytokine
activating STAT family proteins and involved in cell resistance to
treatment. IL-10, as IL-6, is a growth factor for non Hodgkin’s
lymphoma [37] and is often correlated to a poor prognosis [45].
Otero et al. suggested that B cells were resistant to ionizing
radiations through a process involving IL-6 and IL-10, since
knock-out mice for IL-10 as IL-6 become more sensitive to
ionizing radiations. Finally, IL-10 inhibits the pro-apoptotic effect
of doxorubicin on Daudi cells [17]. In this way, our study showed
that high quantity of IL-10 was secreted by resistant cells (U266
and particularly Daudi and Namalwa cells) (Figure 8). We could
envisage a counterbalanced effect of this cytokine in response to
IL-6 inhibition. A close link between IL-10 and IL-6 had been
previously observed for cell signaling and more particularly
concerning STAT3 and SOCS3. IL-10 is able increasing SOCS3
expression in neutrophils [46] and enhancing STAT3 phosphor-
ylation in macrophages for a longer period than IL-6 [47]. We
could hypothesize IL-10 implication for maintaining STAT3
phosphorylation at a high level in Daudi and Namalwa resistant
cells. Thus, silencing of IL-10 mRNA or of common signaling
mediators such as STAT3 could allow highlighting the intercon-
nection between these two cytokine pathways.
Altogether, these data suggest that oncohaematologic cell
response to anticancer treatments like doxorubicin or ionizing
radiations involves a complex network organized around three
main cytokines, IL-6, IL-10 and TNFa, which could be differently
activated according to the cell and the treatment. Interfering with
one member of this network, like IL-6 in our study, seemed to
induce counteracting signals in refractory cells, in attempt to
maintain their proliferation and anti-apoptotic signaling pathways
at a certain level of activation. In consequent, a more precise
knowledge of cytokines and pro-inflammatory proteins engaged in
response to treatment-induced death signals is necessary to identify
the best anticancer therapeutic protocol.
Materials and Methods
Cell culture
Human cancer cells were obtained from ATCC (Manassas, VA,
USA): Daudi: CCL-213, U266: TIB-196, RPMI 8226: CCL-155,
U937: CRL-1593.2, Rs4; 11: CRL-1873, Raji: CCL-86, BL-36:
CCL-87, Ramos: CRL-1596, BJAB: HB-136 and Namalwa:
CRL-1432. Cells were grown in RPMI1640 (Gibco, Carlsbad,
CA, USA), supplemented with 10% decomplemented fetal calf
serum (Lonza, Basel, Switzerland), 10 mL penicillin streptomycin
(10 U/mL/10 mg/mL, Gibco, Carlsbad, CA, USA) and 5 mL
L-glutamin (200 mM, Gibco, Carlsbad, CA, USA) at 37uC
humidified atmosphere containing 5% CO2.
Cell treatments
Cells were exposed to different chemotherapeutic agents
doxorubicin (Teva, Jerusalem, Israel), taxol (Bristol-Myers-Squibb,
Seattle, WA, USA), vinblastine (EG Labo, France) at 0.01, 0.1 and
1 mg/mL, or vincristine (Foulding, Salisbury, South Australia) and
cisplatin (Merck, Darmstadt, Germany) at 0.1, 1 and 10 mg/mL.
Cells were also exposed to 10 mM dexamethasone (Dex, Merck,
Nottingham, UK). Cells were also exposed to 10, 1 or 0.1 mg/mL
of murine anti-IL-6 B-E8 antibody purchased from Diaclone
(Besanc ¸on, France) as compared to the control mouse IgG1 (B-Z1)
(Diaclone, Besanc ¸on, France). Cells were also exposed to 10 mg/
mL of a mouse anti-gp80 IgG1 (B-R6, Diaclone, Besanc ¸on,
France). In signaling experiments, cells were exposed to 10 ng/mL
IL-6 (ebioscience, San Diego, CA, USA) and 50 ng/mL
recombinant IL-6 receptor gp80 or IL-2 receptor (Peprotech,
Rocky Hill, NJ, USA).
RT–PCR
Total RNA was extracted from 5610
6 cells with TrizolH
(Invitrogen, Carlsbad, CA, USA). One microgram of total RNA
was subjected to reverse transcription by using oligodT and
susperscript reverse transcriptase (Invitrogen, Carlsbad, CA,
USA). Amplification of genes of interest IL-6, IL-6R and gp130
was performed with primers designed by Eurogentec (Seraing,
Belgium) as follows: IL-6R-forward : CAT-TGC-CAT-TGT-TCT-
GAG-GTT-C, reverse: AGT-AGT-CTG-TAT-TGC-TGA-TGT-
C; gp130-forward: AGC-CAG-ATT-CCT-CCT-GAA-GAC-A,
reverse: AAG-GTT-TAA-GGT-CTT-GGA-CAG-TGA-A; IL-6-
forward: GTA-CAT-CCT-CGA-CGG-CAT-CTC, reverse: AGC-
CAT-CTT-TGG-AAG-GTT-CAG. PCR was performed for 50
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annealing at 55uC and finally 1 min 30 extension at 72uC. Results
were analyzed by 1.5% agarose gel electrophoresis.
RT–quantitative PCR
cDNA obtained as previously was submitted to RT-qPCR in
SYBR (Eurogentec, Seraing, Belgium): 5 min at 95uC followed by
40 cycles with 15 s at 95uC and 1 min at 60uC. The primers used
were purchased from Eurogentec: IL-6-forward: GTA-CAT-
CCT-CGA-CGG-CAT-CTC, reverse: AGC-CAT-CTT-TGG-
AAG-GTT-CAG; SOCS3-forward: TGG-GAC-GAT-AGC-
AAC-CAC-AA, reverse: CGA-AGT-GTC-CCC-TGT-TTG-
GA, as compared to the tubulin A reference, forward: CCC-
CTT-CAA-GTT-CTA-GTC-ATG-C, reverse: CAT-TGC-CAA-
TCT-GGA-CAC-C.
ELISA
IL-6, soluble gp80 (sgp80) and soluble gp130 (sgp130) levels
were measured in 100 mL supernatants by high sensitivity IL-6,
sIL6R and sgp130 ELISA kits from Diaclone (Besanc ¸on, France),
respectively. Results were recorded with a MRX ELISA micro-
plate reader (Dynex Technologies, Chantilly, VA, USA). IL-10
and TNFa secretion were measured in 100 mL supernatants
obtained as previously with a kit from BenderMedsystem (Vienna,
Austria).
IL-6, IL-6R, and gp130 detection by flow cytometry
For detection of membranous gp130 and gp80, cells were
incubated in serum albumin bovine 10% 30 min at room
temperature, then with 1 mg/mL B-R3 (gp130 antigen), B-R6
(gp80) or B-A11 (CD45) antibodies (Diaclone, Besanc ¸on, France),
30 min at 4uC. The revelation was achieved by using a secondary
antibody Goat anti-Mouse conjugated to phycoerythrin (PE)
(Imgene, San Diego, CA, USA) during 30 min at 4uC. The isotype
controls B-Z1 and B-Z2 (Diaclone, Besanc ¸on, France) were used at
the same concentration for gp80 and gp130, respectively. For
intracytoplasmic detection of IL-6, cells were incubated during 5 h
with Golgi Plug (BD biosciences, San Diego, CA, USA). Then,
2610
5 cells/well were incubated in paraformaldehyde 10%
20 min at 4uC, following with 10 mg/mL B-E8 antibody
(Diaclone, Besanc ¸on, France) 30 min at 4uC, with B-Z1 isotype
as a control and finally with a secondary antibody Goat anti-
Mouse conjugated to PE during 30 min at 4uC.
Proliferation assay
Cells were irradiated at different doses between 7 and 30Gy, or
exposed to the different chemotherapeutic drugs. Cells were
resuspended into fresh medium and plated in 96 well plates at
5000 cells/well. Cell growth was measured 24, 48 and 72 h later
by two methods:
With an ATP-based assay. Twenty mL of Cell Titer Glo
luminescent reagent (Promega, Madison, WI, USA) was added in
100 mL cell suspension for 10 min. Luminescence was recorded
using a Microbeta reader (PerkinElmer, Fremont, CA, USA).
With thymidine incorporation assay. Tritiated thymidine
(GEhealthcare, Chicago, IL, USA) was added during 16 h after
24, 48 and 72 h treatment. Counting was also recorded by the
Microbeta reader.
Apoptosis detection
Annexin V/propidium iodide. The level of living and
apoptotic/necrotic cells was revealed using annexin V-FITC/
propidium iodide (PI) kit (Immunotech, Villepinte, France). 2610
5
cells were incubated with 1 mL annexin V in 200 mL binding
buffer 1X on ice and measurement at FL1-H was performed
10 min later. Five microliters of propidium iodide were then
added to cells and measurement at FL2-H was realized.
Caspase activity. Two tests were used to measure caspase
activity. Total caspase activity was determined through the use of
CaspACE FITC-VAD-FMK in situ Marker (Promega). In brief,
10 mM reagent was added to 10
5 cells 20 min at 37uC before
detection by flow cytometry. Activity of caspases 3 and 7 was also
determined by Caspase-Glo 3/7 assay (Promega). 100 mL of the
luminogenic substrate of caspases Ac-DEVD-pNA was added to
100 mL cell suspension for 1 h. Luminescence was recorded by the
Microbeta reader.
Western blot analysis
Pelleted cells were resuspended in lysis buffer (Tris 50 mM
pH 7.4, NaCl 250 mM, EDTA 5 mM, NaF 50 mM, Triton X-
100 0.1%, orthovanadate 1 mM) plus protease inhibitors for
30 min on ice. After a centrifugation at 14000 rpm for 10 min,
supernatants were boiled for 5 min in Laemmli sample buffer
(Biorad, Hercules, CA, USA). Analysis of protein content was
performed on 4–12% gradient gel. After electrophoretic separa-
tion, 50 mg proteins were electrotransferred on a polyvinylidene
difluoride membrane (Immobilon P, Millipore corp., Bedford,
MA, USA). The membrane was then blocked for 1 h at room
temperature with blocking agent 0.2% in PBS/Tween 0.1%,
probed overnight with a primary rabbit antibody against the
protein of interest, and finally revealed with a secondary anti-
rabbit antibody HRP conjugated (Upstate Biotechnology, Lake
Placid, NY, USA) and ECL Advance system (GEhealthcare,
Chicago, IL, USA). Primary antibody used was obtained from Cell
Signaling (New England Biolabs, Beverly, MA, USA): phospho-
p42/p44 (reference 9101), p42/p44 (4695), phospho-STAT3 (Tyr
705) (9145), phospho-STAT3 (Ser 727) (9134) and STAT-3
(4904), used at 1/1000 to 1/200.
Statistical analysis
Statistical analysis of the differences between various treatment
and control groups was done using a Student’s T test or a
Wilcoxon test. P,0.05 was considered statistically significant.
Supporting Information
Figure S1 Expression of gp130, gp80 and IL-6 in U266, Daudi,
Namalwa and U937 cells. (A) One microgram total RNA was
subjected to RT–PCR for the detection of IL-6, gp130, and gp80,
as described in materials and methods with b2mglobulin as a
control. (B) Membrane staining of gp130 and gp80 or intracellular
staining of IL-6 was performed on 2610
5 cells as described in
materials and methods. The isotype control was shown as an
empty curve. Numbers indicate the percentage of positive cells.
Data shown were representative of two independent experiments.
(C) IL-6, sgp130, and sgp80 levels were measured by ELISA on
100 mL supernatants as described in materials and methods.
Results were expressed as the mean 6 S.D of three independent
experiments realized in duplicate (pg/mL).
Found at: doi:10.1371/journal.pone.0008026.s001 (0.18 MB TIF)
Figure S2 ATP-based proliferation assay was consistent with
thymidine incorporation assay. Daudi cell proliferation was
measured as described in Materials and Methods by two assays,
an ATP-based assay (empty line) or thymidine incorporation assay
(dotted line), at time 24, 48, and 72 h. Results were represented as
the mean of two independent assays realized in duplicate.
Found at: doi:10.1371/journal.pone.0008026.s002 (0.05 MB TIF)
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doxorubicin poorly affected Daudi cell proliferation measured by a
tritiated thymidine test. (A) Cells were irradiated at 7Gy or not
(NI). After irradiation, cells were resuspended into fresh medium,
plated in 96 well plates at 5,000 cells/well and exposed to 10 mg/
mL IgG1 (&) or anti-IL-6 (&) or vehicle (%). Cell growth was
measured 72 h later with 20 mL reagent for 10 min. (B) Cells were
treated for 48 h with 0.1 mg/mL doxorubicin in the presence of
10 mg/mL IgG1(&) or anti-IL-6 (&). Results were expressed as
relative proliferation=number of treated cells at t time/number of
cells at t0 in control conditions6S.D and represented a significant
experiment among two realized in duplicate. The p value was
determined according to a paired T-test * p,0.05, **,0.01. (C)
Cells were exposed or not to 0.1 mg/mL IgG1 or anti–IL-6
antibody for 72 h, then irradiated at 7Gy (&) or not (NI,%) and
treated as previously for 72 h.
Found at: doi:10.1371/journal.pone.0008026.s003 (0.06 MB TIF)
Figure S4 U937 and Daudi cells were sensitive to IL-6 inhibition
following radiations and in the presence of dexamethasone,
respectively. (A) IL-6 protected U937 cells from radiation-induced
cytotoxic effects. U937 cells were exposed or not (NT) to IL-6
10 ng/mL in the presence of 10 mg/mL IgG1 or anti–IL-6 for
72 h, then irradiated (&) or not (NI,%) and treated in the same
conditions than previously for 72 h. Results were expressed as
relative proliferation normalized to t0. (B) A combination of
dexamethasone and anti-IL-6 effectively blocked Daudi cell
proliferation. Daudi cells were treated or not with 0.1 mg/mL
doxorubicin in the presence of 1 mg/mL anti–IL-6 and 10 mM
dexamethasone for 48 h. Results were expressed as % of
proliferation 48 h after treatment normalized to number of
dexamethasone treated cells.
Found at: doi:10.1371/journal.pone.0008026.s004 (0.07 MB TIF)
Figure S5 Anti–IL-6 did not affect radiation-induced caspase
activity. Daudi cells were treated or not (NT) with 10 mg/mL IgG
or anti–IL-6 for 72 h, irradiated at 7Gy or not (NI) and then
treated as before radiations for 72 h. (A) Total caspase activity was
measured by flow cytometry with a caspase inhibitor labelled with
FITC. The isotype control was shown as a green line and
untreated conditions in red line. (B) Caspase 3 and 7 activity was
determined by a luminogenic caspase substrate as described in
Materials and methods. Results were represented as fold caspase
activity induction normalized to the t0 time and represented the
most significant experiment among two realized in duplicate.
Found at: doi:10.1371/journal.pone.0008026.s005 (0.09 MB TIF)
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